Ahmed Hegazy (also: Hegasy; Arabic , Aḥmad Ḥiǧāzī, born October 24, 1939, in Cairo; died February 5, 2021, in Leverkusen) was an Egyptian-German pharmacist. He conducted research in the Pharmaceutical Technology Department of Bayer from 1966 to 1999, during which time he invented a new galenic formulation for the active components nifedipine and nimodipine. By blocking calcium channels, the substance has a relaxing effect on vascular muscles and is therefore used for the treatment of hypertension. In 1991, Hegazy received the Otto Bayer Medal for the solubilization of poorly soluble ingredients such as nimodipine. His galenic invention is still the basis for many modern formulations at Bayer AG (A. Ohm).
Attributes | Values |
---|
rdf:type
| |
rdfs:label
| - Ahmed Hegazy (Pharmazeut) (de)
- Ahmed Hegazy (pharmacist) (en)
|
rdfs:comment
| - Ahmed Hegazy (also: Hegasy; Arabic , Aḥmad Ḥiǧāzī, born October 24, 1939, in Cairo; died February 5, 2021, in Leverkusen) was an Egyptian-German pharmacist. He conducted research in the Pharmaceutical Technology Department of Bayer from 1966 to 1999, during which time he invented a new galenic formulation for the active components nifedipine and nimodipine. By blocking calcium channels, the substance has a relaxing effect on vascular muscles and is therefore used for the treatment of hypertension. In 1991, Hegazy received the Otto Bayer Medal for the solubilization of poorly soluble ingredients such as nimodipine. His galenic invention is still the basis for many modern formulations at Bayer AG (A. Ohm). (en)
- Ahmed Hegazy (auch: Hegasy; arabisch أحمد حجازي, DMG Aḥmad Ḥiǧāzī, geb. am 24. Oktober 1939 in Kairo; gest. am 5. Februar 2021 in Leverkusen) war ein ägyptisch-deutscher Galeniker. Er forschte von 1966 bis 1999 in der Abteilung Pharmazeutische Technologie der Bayer AG und entwickelte in dieser Zeit eine neue Darreichungsform des Arzneistoffs Nifedipin zur Behandlung von Bluthochdruck. 1991 erhielt er für die Solubilisierung schwerlöslicher Wirkstoffe wie Nifedipin die Otto-Bayer-Medaille. Diese galenische Erfindung ist noch heute Grundlage für viele moderne Formulierungen der Bayer AG (A. Ohm). (de)
|
foaf:depiction
| |
dcterms:subject
| |
Wikipage page ID
| |
Wikipage revision ID
| |
Link from a Wikipage to another Wikipage
| |
Link from a Wikipage to an external page
| |
sameAs
| |
dbp:wikiPageUsesTemplate
| |
thumbnail
| |
has abstract
| - Ahmed Hegazy (also: Hegasy; Arabic , Aḥmad Ḥiǧāzī, born October 24, 1939, in Cairo; died February 5, 2021, in Leverkusen) was an Egyptian-German pharmacist. He conducted research in the Pharmaceutical Technology Department of Bayer from 1966 to 1999, during which time he invented a new galenic formulation for the active components nifedipine and nimodipine. By blocking calcium channels, the substance has a relaxing effect on vascular muscles and is therefore used for the treatment of hypertension. In 1991, Hegazy received the Otto Bayer Medal for the solubilization of poorly soluble ingredients such as nimodipine. His galenic invention is still the basis for many modern formulations at Bayer AG (A. Ohm). (en)
- Ahmed Hegazy (auch: Hegasy; arabisch أحمد حجازي, DMG Aḥmad Ḥiǧāzī, geb. am 24. Oktober 1939 in Kairo; gest. am 5. Februar 2021 in Leverkusen) war ein ägyptisch-deutscher Galeniker. Er forschte von 1966 bis 1999 in der Abteilung Pharmazeutische Technologie der Bayer AG und entwickelte in dieser Zeit eine neue Darreichungsform des Arzneistoffs Nifedipin zur Behandlung von Bluthochdruck. 1991 erhielt er für die Solubilisierung schwerlöslicher Wirkstoffe wie Nifedipin die Otto-Bayer-Medaille. Diese galenische Erfindung ist noch heute Grundlage für viele moderne Formulierungen der Bayer AG (A. Ohm). (de)
|
prov:wasDerivedFrom
| |
page length (characters) of wiki page
| |
foaf:isPrimaryTopicOf
| |
is Link from a Wikipage to another Wikipage
of | |
is foaf:primaryTopic
of | |